Tango Therapeutics (TNGX) Competitors $7.87 +0.25 (+3.28%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$7.78 -0.09 (-1.21%) As of 09/18/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX vs. MOR, IMVT, XENE, VKTX, OGN, KNSA, NAMS, BHC, GMTX, and CGONShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include MorphoSys (MOR), Immunovant (IMVT), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Its Competitors MorphoSys Immunovant Xenon Pharmaceuticals Viking Therapeutics Organon & Co. Kiniksa Pharmaceuticals International NewAmsterdam Pharma Bausch Health Cos Gemini Therapeutics CG Oncology MorphoSys (NASDAQ:MOR) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Does the media refer more to MOR or TNGX? In the previous week, Tango Therapeutics had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Tango Therapeutics and 0 mentions for MorphoSys. Tango Therapeutics' average media sentiment score of 0.88 beat MorphoSys' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Tango Therapeutics Positive Do insiders and institutionals hold more shares of MOR or TNGX? 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 7.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings & valuation, MOR or TNGX? Tango Therapeutics has lower revenue, but higher earnings than MorphoSys. Tango Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Tango Therapeutics$42.07M20.81-$130.30M-$1.33-5.92 Is MOR or TNGX more profitable? MorphoSys has a net margin of -226.79% compared to Tango Therapeutics' net margin of -599.11%. Tango Therapeutics' return on equity of -79.72% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Tango Therapeutics -599.11%-79.72%-49.30% Which has more volatility & risk, MOR or TNGX? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Do analysts recommend MOR or TNGX? Tango Therapeutics has a consensus target price of $10.50, indicating a potential upside of 33.42%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTango Therapeutics beats MorphoSys on 12 of the 16 factors compared between the two stocks. Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$847.80M$3.12B$5.78B$10.27BDividend YieldN/A2.37%5.74%4.64%P/E Ratio-5.9221.3676.5226.98Price / Sales20.81479.50546.03182.41Price / CashN/A45.3237.1760.63Price / Book4.239.6913.886.37Net Income-$130.30M-$52.92M$3.29B$271.46M7 Day Performance20.52%2.19%1.60%2.53%1 Month Performance13.07%8.96%6.89%9.42%1 Year Performance-6.42%10.84%82.40%30.16% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics2.1582 of 5 stars$7.87+3.3%$10.50+33.4%-5.0%$847.80M$42.07M-5.9290Insider TradeHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant2.3311 of 5 stars$15.53-3.9%$33.60+116.4%-46.7%$2.82BN/A-5.45120XENEXenon Pharmaceuticals2.4159 of 5 stars$35.99-0.6%$53.30+48.1%-5.8%$2.79B$7.50M-10.14210Positive NewsOptions VolumeVKTXViking Therapeutics4.2775 of 5 stars$24.08-2.9%$87.50+263.4%-59.6%$2.79BN/A-15.7420OGNOrganon & Co.4.5577 of 5 stars$10.39-2.5%$17.33+66.9%-45.6%$2.77B$6.40B3.864,000Positive NewsKNSAKiniksa Pharmaceuticals International2.4516 of 5 stars$36.56-1.5%$41.17+12.6%+42.1%$2.75B$423.24M914.23220Insider TradeShort Interest ↑NAMSNewAmsterdam Pharma3.3157 of 5 stars$24.12-0.3%$41.55+72.2%+67.6%$2.72B$45.56M-14.894Positive NewsBHCBausch Health Cos4.6113 of 5 stars$7.17-1.2%$9.00+25.5%-13.6%$2.69B$9.86B27.5820,700Positive NewsGMTXGemini TherapeuticsN/A$59.82-0.8%N/A+28.1%$2.59BN/A-59.8230News CoverageCGONCG Oncology2.6824 of 5 stars$34.60+3.8%$53.91+55.8%+4.7%$2.54B$1.14M-19.5561Analyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies MOR Competitors IMVT Competitors XENE Competitors VKTX Competitors OGN Competitors KNSA Competitors NAMS Competitors BHC Competitors GMTX Competitors CGON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNGX) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
